The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Hogg, Kirsten ^a   Wood, Charlotte ^a   McNeilly, Alan S ^a   Duncan, W Colin ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CERAMIDE GLUCOSYLTRANSFERASE; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SOMATOMEDIN C; TESTOSTERONE PROPIONATE; GLUCOSYLTRANSFERASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP);

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPIGENETICS; EWE; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN RELEASE; LIVER FUNCTION; LIVER METABOLISM; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRENATAL EXPOSURE; SHEEP; UPREGULATION; ANIMAL; DRUG EFFECT; LIVER; METABOLISM; OVARY POLYCYSTIC DISEASE; PREGNANCY;

ANIMALIA; OVIS ARIES;

ANIMALS; FEMALE; GLUCOSYLTRANSFERASES; LIVER; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); POLYCYSTIC OVARY SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; SHEEP; TESTOSTERONE PROPIONATE;

EID: 80052830410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024877     Document Type: Article

References (55)

1. Nicoletto SF, Rinaldi A, (2011) In the womb's shadow. EMBO Rep 12: 30-34.
2. Barker DJP, (2004) The Developmental Origins of Adult Disease. J Am Coll Nutr 23: 588S-595.
3. Maric C, (2007) Mechanisms of Fetal Programming of Adult Hypertension: Role of Sex Hormones. Hypertension 50: 605-606.
4. Lillycrop KA, Burdge GC, (2011) Epigenetic changes in early life and future risk of obesity. Int J Obes 35: 72-83.
5. Abbott DH, Dumesic DA, Franks S, (2002) Developmental origin of polycystic ovary syndrome- a hypothesis. J Endocrinol 174: 1-5.
6. Franks S, (1995) Polycystic Ovary Syndrome. N Engl J Med 333: 853-861.
7. Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW, (1998) Insights into the Development of Polycystic Ovary Syndrome (PCOS) from Studies of Prenatally Androgenized Female Rhesus Monkeys. Trends Endocrinol Metab 9: 62-67.
8. Birch RA, Padmanabhan V, Foster DL, Unsworth WP, Robinson JE, (2003) Prenatal Programming of Reproductive Neuroendocrine Function: Fetal Androgen Exposure Produces Progressive Disruption of Reproductive Cycles in Sheep. Endocrinology 144: 1426-1434.
9. Eisner JR, Barnett MA, Dumesic DA, Abbott DH, (2002) Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 77: 167-172.
10. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, et al. (2007) A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome. Endocrinology 148: 3781-3791.
11. West C, Foster DL, Evans NP, Robinson J, Padmanabhan V, (2001) Intra-follicular activin availability is altered in prenatally-androgenized lambs. Mol Cell Endocrinol 185: 51-59.
12. Sharma TP, Herkimer C, West C, Ye W, Birch R, et al. (2002) Fetal Programming: Prenatal Androgen Disrupts Positive Feedback Actions of Estradiol but Does Not Affect Timing of Puberty in Female Sheep. Biol Reprod 66: 924-933.
13. Veiga-Lopez A, Ye W, Phillips DJ, Herkimer C, Knight PG, et al. (2008) Developmental Programming: Deficits in Reproductive Hormone Dynamics and Ovulatory Outcomes in Prenatal, Testosterone-Treated Sheep. Biol Reprod 78: 636-647.
14. Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren SE, Herkimer C, (2010) Developmental Programming: Impact of Prenatal Testosterone Excess and Postnatal Weight Gain on Insulin Sensitivity Index and Transfer of Traits to Offspring of Overweight Females. Endocrinology 151: 595-605.
15. Recabarren SE, Padmanabhan V, Codner E, Lobos A, Duran C, et al. (2005) Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab 289: E801-806.
16. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, et al. (2006) Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease in Young Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 91: 1741-1747.
17. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB, (2005) Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 83: 494-497.
18. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, et al. (2010) Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25: 212-220.
19. Brzozowska M, M., Ostapowicz G, Weltman M, D, (2009) An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroen Hepatol 24: 243-247.
20. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, et al. (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47: 412-417.
21. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic Fatty Liver Disease. Diabetes 50: 1844-1850.
22. Mayes JS, Watson GH, (2004) Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 5: 197-216.
23. Kissebah AH, Peiris AN, (1989) Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 5: 83-109.
24. Dunaif A, Segal KR, Futterweit W, Dobrjansky A, (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174.
25. Veiga-Lopez A, Steckler TL, Abbott DH, Welch KB, MohanKumar PS, et al. (2011) Developmental Programming: Impact of Excess Prenatal Testosterone on Intrauterine Fetal Endocrine Milieu and Growth in Sheep. Biol Reprod 84: 87-96.
26. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, et al. (2007) Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5: 496-501.
27. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, et al. (2009) Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 32: 695-700.
28. Savabieasfahani M, Lee JS, Herkimer C, Sharma TP, Foster DL, et al. (2005) Fetal Programming: Testosterone Exposure of the Female Sheep During Midgestation Disrupts the Dynamics of Its Adult Gonadotropin Secretion During the Periovulatory Period. Biol Reprod 72: 221-229.
29. Lockman KA, Nyirenda MJ, (2010) Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease. Curr Diabetes Rev 6: 341-347.
30. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG, (2005) {beta}-Cell Function: A Key Pathological Determinant in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 90: 310-315.
31. Dunaif A, Finegood DT, (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 942-947.
32. Hogg K, McNeilly AS, Duncan WC, (2011) Prenatal Androgen Exposure Leads to Alterations in Gene and Protein Expression in the Ovine Fetal Ovary. Endocrinology 152: 2048-2059.
33. Steckler T, Manikkam M, Inskeep EK, Padmanabhan V, (2007) Developmental Programming: Follicular Persistence in Prenatal Testosterone-Treated Sheep Is Not Programmed by Androgenic Actions of Testosterone. Endocrinology 148: 3532-3540.
34. Masek KS, Wood RI, Foster DL, (1999) Prenatal Dihydrotestosterone Differentially Masculinizes Tonic and Surge Modes of Luteinizing Hormone Secretion in Sheep. Endocrinology 140: 3459-3466.
35. Veiga-Lopez A, Astapova OI, Aizenberg EF, Lee JS, Padmanabhan V, (2009) Developmental Programming: Contribution of Prenatal Androgen and Estrogen to Estradiol Feedback Systems and Periovulatory Hormonal Dynamics in Sheep. Biol Reprod 80: 718-725.
36. Rognstad R, (1979) Rate-limiting steps in metabolic pathways. J Biol Chem 254: 1875-1878.
37. Chakravarty K, Cassuto H, Reshef L, Hanson RW, (2005) Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Criti Rev Biochem Mol Biol 40: 129-154.
38. Valera A, Pujol A, Pelegrin M, Bosch F, (1994) Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 91: 9151-9154.
39. She P, Shiota M, Shelton KD, Chalkley R, Postic C, et al. (2000) Phosphoenolpyruvate Carboxykinase Is Necessary for the Integration of Hepatic Energy Metabolism. Mol Cell Biol 20: 6508-6517.
40. Owen OE, Kalhan SC, Hanson RW, (2002) The Key Role of Anaplerosis and Cataplerosis for Citric Acid Cycle Function. J Biol Chem 277: 30409-30412.
41. Hakimi P, Johnson M, Yang J, Lepage D, Conlon R, et al. (2005) Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab 2: 33.
42. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, et al. (2008) Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294: G1281-G1287.
43. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, et al. (1998) SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci U S A 95: 6881-6886.
44. Ichikawa S, Sakiyama H, Suzuki G, Hidari KI, Hirabayashi Y, (1996) Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci U S A 93: 4638-4643.
45. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, et al. (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48: 634-642.
46. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, et al. (2001) Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183-1192.
47. Baxter RC, (2000) Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol- Endocrinol Metab 278: E967-E976.
48. Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ, (2004) Association between Insulin-Like Growth Factor-I: Insulin-Like Growth Factor-Binding Protein-1 Ratio and Metabolic and Anthropometric Factors in Men and Women. Cancer Epidemiol Biomarkers Prev 13: 166-170.
49. Mogul HR, Marshall M, Frey M, Burke HB, Wynn PS, et al. (1996) Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 81: 4492-4495.
50. Buyalos RP, Pekonen F, Halme JK, Judd HL, Rutanen E-M, (1995) The relationship between circulating androgens, obesity, and hyperinsulinemia on serum insulin-like growth factor binding protein-1 in the polycystic ovarian syndrome. Am J Obstet Gynecol 172: 932-939.
51. Suikkari A-M, Ruutiainen K, Erkkola R, Sepälä M, (1989) Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease. Hum Reprod 4: 136-139.
52. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, et al. (2007) Identification of Androgen Response Elements in the Insulin-Like Growth Factor I Upstream Promoter. Endocrinology 148: 2984-2993.
53. McNatty KP, Baird DT, Bolton A, Chambers P, Corker CS, et al. (1976) Concentration of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. J Endocrinol 71: 77-85.
54. Corker CS, Davidson DW, (1978) A radioimmunoassay for testosterone in various biological fluids without chromatography. J Steroid Biochem 9: 373-374.
55. Rozen S, Skaletsky HJ, (2000) Primer3 on the WWW for general users and for biologist programmers. In: S K, S M, editors. Bioinformatics Methods and Protocols: Methods in Molecular Biology. 365-386 Totowa, NJ Humana Press.